BLRX vs. CLSD, VRCA, ACHL, NRXP, TELO, RENB, OTLK, HOWL, QNTM, and IRD
Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Clearside Biomedical (CLSD), Verrica Pharmaceuticals (VRCA), Achilles Therapeutics (ACHL), NRx Pharmaceuticals (NRXP), Telomir Pharmaceuticals (TELO), Renovaro (RENB), Outlook Therapeutics (OTLK), Werewolf Therapeutics (HOWL), Quantum Biopharma (QNTM), and Opus Genetics (IRD). These companies are all part of the "pharmaceutical products" industry.
BioLineRx vs. Its Competitors
Clearside Biomedical (NASDAQ:CLSD) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
18.8% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 6.2% of Clearside Biomedical shares are owned by company insiders. Comparatively, 1.1% of BioLineRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, BioLineRx had 1 more articles in the media than Clearside Biomedical. MarketBeat recorded 2 mentions for BioLineRx and 1 mentions for Clearside Biomedical. Clearside Biomedical's average media sentiment score of 0.95 beat BioLineRx's score of 0.00 indicating that Clearside Biomedical is being referred to more favorably in the media.
BioLineRx has higher revenue and earnings than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
BioLineRx received 133 more outperform votes than Clearside Biomedical when rated by MarketBeat users. Likewise, 71.43% of users gave BioLineRx an outperform vote while only 67.32% of users gave Clearside Biomedical an outperform vote.
BioLineRx has a net margin of -15.21% compared to Clearside Biomedical's net margin of -818.57%. Clearside Biomedical's return on equity of 0.00% beat BioLineRx's return on equity.
Clearside Biomedical has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
Clearside Biomedical currently has a consensus price target of $4.80, indicating a potential upside of 471.56%. BioLineRx has a consensus price target of $26.00, indicating a potential upside of 513.21%. Given BioLineRx's stronger consensus rating and higher probable upside, analysts clearly believe BioLineRx is more favorable than Clearside Biomedical.
Summary
BioLineRx beats Clearside Biomedical on 11 of the 19 factors compared between the two stocks.
Get BioLineRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLineRx Competitors List
Related Companies and Tools
This page (NASDAQ:BLRX) was last updated on 6/23/2025 by MarketBeat.com Staff
